L

Lineage Cell Therapeutics Inc
TASE:LCTX

Watchlist Manager
Lineage Cell Therapeutics Inc
TASE:LCTX
Watchlist
Price: 345.1 ILS 5.54%
Market Cap: 173.6m ILS

Wall Street
Price Targets

LCTX Price Targets Summary
Lineage Cell Therapeutics Inc

Wall Street analysts forecast LCTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LCTX is 1 300.97 ILS with a low forecast of 493.36 ILS and a high forecast of 3 077.37 ILS.

Lowest
Price Target
493.36 ILS
43% Upside
Average
Price Target
1 300.97 ILS
277% Upside
Highest
Price Target
3 077.37 ILS
792% Upside
Lineage Cell Therapeutics Inc Competitors:
Price Targets
6160
Beigene Ltd
13% Upside
4BB
4Basebio PLC
73% Upside
PTGX
Protagonist Therapeutics Inc
35% Upside
FLUO
Fluoguide AS
164% Upside
603087
Gan & Lee Pharmaceuticals
13% Upside
AKBA
Akebia Therapeutics Inc
89% Upside
600161
Beijing Tiantan Biological Products Corp Ltd
53% Upside
AMGN
Amgen Inc
8% Upside

Revenue
Forecast

Revenue Estimate
Lineage Cell Therapeutics Inc

For the last 8 years the compound annual growth rate for Lineage Cell Therapeutics Inc's revenue is 6%. The projected CAGR for the next 3 years is 78%.

6%
Past Growth
78%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Lineage Cell Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Net Income
Forecast

Net Income Estimate
Lineage Cell Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-31%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LCTX's stock price target?
Price Target
1 300.97 ILS

According to Wall Street analysts, the average 1-year price target for LCTX is 1 300.97 ILS with a low forecast of 493.36 ILS and a high forecast of 3 077.37 ILS.

What is Lineage Cell Therapeutics Inc's Revenue forecast?
Projected CAGR
78%

For the last 8 years the compound annual growth rate for Lineage Cell Therapeutics Inc's revenue is 6%. The projected CAGR for the next 3 years is 78%.

Back to Top